-
With the acceleration of the development of the pharmaceutical industry, enterprises are accelerating to make up for the shortcomings of talents
Time of Update: 2022-10-03
In addition, Dongfulong also mentioned in the interim report that the company increased its research and development personnel in the first half of the year.
In addition, Dongfulong also mentioned in the interim report that the company increased its research and development personnel in the first half of the year.
-
Domestic microsphere preparations are expected to usher in an explosive period, and pharmaceutical machinery enterprises actively expand the business layout of microspheres
Time of Update: 2022-10-03
With the continuous innovation of microsphere preparation technology and the accelerated layout of domestic pharmaceutical companies, the industry expects that the market size of microsphere drugs in chronic disease-related fields such as malignant tumors, heart diseases, cerebrovascular diseases will continue to grow, and is expected to usher in an outbreak period.
-
Junshi Biologics' JS110 (XPO1 inhibitor) clinical trial application was approved by the US FDA
Time of Update: 2022-10-03
Shanghai, August 25, 2022 /PRNewswire/ -- On August 25, 2022, Beijing time, Junshi Biologics announced that the clinical trial application of the XPO1 inhibitor WJ01024 tablets (project code: JS110) jointly developed by the company and Micro Bio has been approved by the US Food and Drug Administration (FDA).
-
2022 Biological Fermentation Exhibition - Brand enterprises have settled in to seize the opportunity, who comes to the feast
Time of Update: 2022-10-03
The 10th Shanghai Biological Fermentation Products & Technology Equipment Exhibition (hereinafter referred to as BIO CHINA 2022) will be held on December 1-3, 2022 at Shanghai New International Expo Center.
-
Seasonal flu is on the rise again! Be aware of these for flu vaccination
Time of Update: 2022-10-03
Xu Baoping, director of the Department of Respiratory Medicine of Beijing Children's Hospital of the National Children's Medical Center: Children are high-risk groups of influenza, especially children younger than 5 years old, or children less than 2 years old, and they will definitely have lower respiratory tract infections after suffering from influenza, such as influenza pneumonia; There are other types of complications, such as central nervous system complications, cardiovascular system, myocardial damage, etc.
-
With the rapid development of the traditional Chinese medicine industry, all localities are vigorously cultivating professional talents
Time of Update: 2022-10-03
On September 17th, Anhui Province Traditional Chinese Medicine Revitalization and Development Conference was held in Hefei. At the meeting, it was proposed that all localities and relevant departments
-
Innovative drug companies and Chinese medicine companies have a large number of general managers leaving!
Time of Update: 2022-10-03
Since the beginning of this year, the senior management of pharmaceutical companies has changed, and a large number of senior executives such as general managers of pharmaceutical companies have resigned for personal reasons, work adjustments and other reasons, and it has been particularly frequent since the second half of the year.
-
Innovation in traditional Chinese medicine continues to accelerate, and pharmaceutical companies are using digital technology to promote industrial upgrading
Time of Update: 2022-10-03
Chinese medicine pharmaceutical companies are using digital technology to promote industrial upgrading (Source: Pharmaceutical Network) It is understood that in recent years, benefiting from the support of a series of favorable policies, the strategic position of traditional Chinese medicine is constantly improving.
-
A large number of pharmaceutical companies are looking for new business opportunities in improved new drugs!
Time of Update: 2022-10-03
For example, in April, Beijing Aoxin Sunshine, a MAH company focusing on improved innovative drugs, was founded by a number of senior scientists of pharmaceutical companies in China, and was built in three phases with a total investment of 120 million yuan.
-
Yasheng Pharmaceutical announced its 2022 interim results: the commercialization of Nerick ® has accelerated, and the key pipeline varieties have gradually entered the harvest period
Time of Update: 2022-10-03
Suzhou, China and Rockville, Maryland, USA, 27 August 2022 /PRNewswire/ -- AsiaPharma, a leading biopharmaceutical company dedicated to developing innovative drugs in therapeutic areas such as oncolog
-
Dekang Tongzhi Rhinitis ® Granules won the "2021~2022 Chinese Family Regular Medicine Listed Brand"
Time of Update: 2022-10-03
Recently, the "2021-2022 China Family Shelf Medicine Listed Brands", which is loved by the public, authoritative, professional, convenient and practical, was officially released to the public. The eve
-
Do a good job in "prevention", "control" and "treatment" - in the past ten years, China's endemic disease prevention and control has achieved historic results
Time of Update: 2022-10-03
In the past ten years, no new endemic cretinosis patients have been found in China, iodine deficiency disease has reached a continuous elimination state, there are basically no new cases of osteoarthritis in China, and the number of soil-derived nematodes and foodborne parasitic infections has decreased significantly.
-
Aiming at the NASH drug market of more than 30 billion yuan, nearly 20 domestic pharmaceutical companies are actively deployed!
Time of Update: 2022-10-03
Recently, the American biotechnology company Akaro released positive data on its new NASH drug Efruxifermin in the Phase IIb HARMONY study, which has attracted great attention from the industry, and the drug has once again pushed NASH, the field of disease treatment research and development.
-
Is there still an opportunity in the pharmaceutical sector in the fourth quarter? The industry is optimistic about these subdivision tracks
Time of Update: 2022-10-03
The industry believes that after the valuation digestion of the CXO sector in the past two years or so, the overall valuation has returned to a more reasonable range, and the low allocation value of the plate is highlighted in the long run.
-
In order to cope with the challenges of transformation or upgrading, M&A activities of pharmaceutical companies are becoming increasingly enthusiastic
Time of Update: 2022-10-03
In addition, Huadong Pharmaceutical also announced on August 9 that it will invest a total of no more than 396 million yuan to acquire 60% of the equity of Huaren Technology.
-
Advance Media's interim results: Strong growth of the business twin engines, strong marketing system to promote the full commercialization
Time of Update: 2022-10-02
Key Operating Summary: Despite the impact of the epidemic in the first half of the year, sales of transcatheter valve therapy business and neurointervention business were strong, with revenue of RMB52.
-
Under the acceleration of aging, it may stimulate the innovation and upgrading of drugs and devices
Time of Update: 2022-10-02
Under the acceleration of aging, it may stimulate drugs and devices to accelerate innovation and upgrading (Source: Pharmaceutical Network) The demand for innovative drugs will continue to increase in the future The demand for innovative drugs will continue to increase in the future After the human body enters old age, the function declines, including cardiovascular and cerebrovascular diseases, diabetes, tumors and other diseases will increase, and the demand for related treatment new drugs will also increase.
-
Pfizer sold the factory, Suqiao was acquired, Kewang "optimized production capacity", and the self-built factory building was "not fragrant"?
Time of Update: 2022-10-02
Earlier, WuXi Biologics CEO Chen Zhisheng once said: "Some companies have built factories that exceed their own needs or capabilities, and now there is a 'factory building tide' in China, what will be the situation in five years?" ” China's biomedical industry is developing rapidly, and in recent years, many enterprises have increased their efforts to build their own factories and expand production capacity.
-
Analysis of the current situation and competitive landscape of the oral drug market
Time of Update: 2022-10-02
Dentistry belongs to the Department of Stomatology, in the PDB database, dental drugs do not have a separate treatment sub-category, so this paper analyzes the sales amount and changes of dental drugs, mainly and several key drugs used in dentistry in sample hospitals, average unit price, etc.
-
The invested enterprise of Huaxing Medical Industry Fund, Oppmai, landed on the science and technology innovation board and opened sharply on the first day
Time of Update: 2022-10-02
On September 2, Shanghai Opmeg Biotechnology Co. , Ltd. (hereinafter referred to as "Opme"), known as the first share of cell culture media in China, officially landed on the Science and Technology I
